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 Cap homeostasis is a cyclical process of 5’ mRNA cap removal followed by re-
addition of the cap (“recapping”) that affects a subset of mRNA transcripts. Uncapped 
targets of recapping can accumulate in the cytoplasm, and cytoplasmic recapping is all 
that is needed for the return of these transcripts to the actively translating pool. Cap 
homeostasis is a unique mechanism for post-transcriptional gene regulation, but the 
biological applications of cytoplasmic recapping are still not well understood. The 
current study aims to establish novel protein interactors of cytoplasmic capping enzyme 
(cCE), a core member of the protein machinery that is necessary to perform recapping. 
Using proximity-dependent biotin identification (BioID), interactors of cCE are biotin-
tagged in vivo and identified by western blotting and mass spectrometry. Here, I discuss 
the implications of identified cCE interactors for cap homeostasis as well as introduce 




The central dogma of RNA biology in eukaryotes states that mRNA transcripts 
are produced in the nucleus and are matured through a series of step-wise 
modifications. These modifications include the addition of a 5’ m7G cap structure, 
addition of a polyA stretch of residues at the 3’ end, and splicing of introns (15). Mature 
mRNA then exits the nucleus by localizing to the nuclear pore complex and 
translocating into the cytoplasm (5). Once in the cytoplasm, mRNA is subject to 
translation from free or membrane bound ribosomes. The efficiency of translation of any 
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given mRNA depends on a variety of factors, but perhaps most importantly the 
maintenance of an intact 5’ cap (5). The cap protects the transcript from degradation by 
cytoplasmic exonuclease enzymes and recruits translation machinery necessary for 
normal protein expression (5). Eventually, all transcripts will be subject to de-capping 
and degradation, a process known as RNA turnover. This signals the end of transcript 
expression. It was previously thought that the loss of the 5’ mRNA cap is an important 
signal that an mRNA has begun the irreversible process of turnover. 
In addition to stabilizing mRNAs, there is also evidence that a mature m7G cap 
structure is necessary to recruit multiple cap-binding complexes (CBCs) both in the 
nucleus and cytoplasm. The cap can recruit factors necessary for spliceosome 
assembly (1) on the pre-mRNA as well as 3’ end processing factors that bind at the 
polyA site in the nucleus (2). Both of these steps are essential to produce mature 
mRNA. CBC binding to transcripts is also thought to be essential for mRNA nuclear 
export in higher eukaryotes, in which associations between CBC proteins and nuclear 
export machinery at the nuclear envelope mediates export through the pore with 5’ to 3’ 
(3,4). Once in the cytoplasm, the cap indirectly recruits the initiator tRNA and ribosomal 
subunits via CBCs comprised of translation initiation factors (5). Cap formation then is 
critical for the first round of translation and maintenance of translation throughout the 





The eukaryotic mRNA cap consists of an inverted guanosine triphosphate 
residue that is methylated at position N7. This m7 modification on the guanosine 
residue is necessary to maintain a functional cap structure (11). A second methylation 
occurs at the +1 nucleotide at the 2’O position. This modification enables the cell to 
discriminate between its own transcript population and potentially harmful viral gene 
products, and serves as an immune defense (5). Traditionally, formation of an intact cap 
was thought to occur only in the nucleus via a series of stepwise modifications. These 
modifications include: 1) γ-phosphate cleavage of the nascent 5’ triphosphate, 2) 
guanosine residue addition to this diphosphate intermediate, and 3) proper methylations 
at the N7 and 2’O positions as described above (6). The first two reactions are 
catalyzed by capping enzyme (CE) and the N7 methylation is catalyzed by cap-
methyltransferase (RNMT). One prediction of the hypothesis that 5’ capping only 
Figure 1: Eukaryotic mRNA cap consists of an inversely-oriented guanosine residue (left) 
that is linked to the first transcribed nucleotide (right) through a triphosphate bridge. 
The cap also consists of two methylations. The first methylation is at the N-7 position 
on the G-cap, and the second methylation is at the 2’O position on the first transcribed 
nucleotide.  (Source: 5) 
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occurred in the nucleus is that the identified cap-building enzymes are only functioning 
in the nucleus, where mRNA maturation takes place. However, an initial observation of 
5’ truncated forms of nonsense-containing mRNA that appeared to have a re-
constituted cap structure led to the idea that there may be capping machinery in the 
cytoplasm (6). In addition, CE was shown to also have a cytoplasmic expression pattern 
(6). This, along with similar observations of cytoplasmic distributions of other capping 
factors, eventually led to the idea of an enzymatically active cytoplasmic capping 











In the cytoplasm, generation of a re-constituted cap diverges slightly from initial 
nuclear cap formation. The primary reaction is catalyzed by an unidentified cytoplasmic 
kinase which transfers the γ-phosphate of ATP to an uncapped 5’ monophosphate end 
Figure 2: Early model of the cytoplasmic capping complex. An uncapped, 
monophosphate end is modified to a diphosphate end by an unknown 
cytoplasmic kinase. Capping enzyme present in the cytoplasm catalyzes 
addition of GMP to the phosphate end to create an unmethylated cap 
structure. An unknown methyltransferase (now understood to be RNMT) 
catalyzes m7 methylation. CE is mound via its C-terminus to Nck1, an adapter 
protein that also recruits monophosphate kinase activity. (Source 7) 
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of mRNA, generating a diphosphate end which can be recognized by cCE. cCE 
transgene expression and subsequent recovery using magnetic beads identified 
adapter protein Nck1’s third SH3 domain as a binding partner of cCE. In vitro 5’ kinase 
activity was found to be dependent on an intact second SH2 domain of Nck1 (7). These 
data along with evidence that cytoplasmic capping functionality is dependent on Nck1(7) 
led to the modern hypothesis of the cytoplasmic capping complex. Nck1 acts as a 
scaffold to bind the catalytic subunits of the cytoplasmic capping reactions and serves to 
increase re-capping efficiency by increasing the local concentration of recapping 
enzymes (7). 
The specific biological use of cytoplasmic capping is not well understood, 
although it is thought to assist in cell recovery from stress (6). In general, cytoplasmic 
recapping is thought to restore inactive transcripts to a translationally active state, a 
phenomenon known as cap homeostasis (7). Cap homeostasis could provide a 
mechanism for the cell to express certain proteins when stressed, when translation is 
largely inhibited (6). Cytoplasmic recapping could also provide a fast way to respond to 
various internal or external stimuli. Re-activating existing cytoplasmic transcripts would 
allow the cell to change protein expression, and this response would be far quicker than 
the cell synthesizing new gene products and moving them to various subcellular 
locations. To this end, cytoplasmic recapping could be useful to change protein 
expression at a local level, since recapping can only occur where uncapped yet 
otherwise intact transcripts have accumulated. The intriguing potential for cytoplasmic 




 The goal of the current study is multifold. The first aim was to develop proximity-
dependent biotinylation in the context of cytoplasmic capping as a mechanism by which 
to study the protein factors involved in the cytoplasmic capping process. Once 
established, this system was used to validate already proposed members of the core 
cytoplasmic capping complex, including those described above. Most importantly, this 
study aims to establish cCE as a potentially multifunctional protein within a vast 
proteome and begin to characterize its relationship to other proteins that have not yet 
been considered in the context of cytoplasmic capping. 
 The identification of protein interactors in this study uses a technique called 
“proximity-dependent biotin identification” (BioID) which was first developed and used 
by the lab of Kyle Roux in 2012 to survey protein interactors of Lamin-A, a component 
of the nuclear envelope (8). The utility of BioID over more traditional protein 
identification techniques (namely isolation of interactors via pulldown using a bait 
protein of interest) is that BioID can tag interacting proteins with biotin in vivo. While 
traditional methods provide a snapshot of bound proteins at any given moment, in vivo 
tagging documents a history of protein interactions over the labeling time course. The 
BioID approach should provide a more robust profile of protein interactors to a protein of 
interest than a parallel traditional pulldown. This is because BioID’s ability to tag even 
transient interactors with lower affinity to a protein of interest can provide a mechanism 
for isolation that a traditional pulldown technique does not provide. Without a biotin tag 
that can be recognized, these loosely associated proteins would be washed away 
during processing of pulldown samples.   
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 BioID uses the biotin ligase protein BirA that comes from Escherichia coli. Its 
wild-type function is to act as a repressor in the biotin biosynthesis operon (9) and its 
tagging ability is highly specific to a single substrate in E. coli. For the purpose of 
tagging mammalian proteins, the Roux lab chose a BirA mutant (R118G) termed BirA*. 
Unlike the extremely specific wild-type protein, BirA* “promiscuously” tags proteins in a 
proximity-dependent fashion and does not require the presence of a biotin acceptor tag 
(BAT) necessary for wild-type tagging. BirA* biotin tags proteins in a two-step process. 
The first step is a free ATP addition to biotin to create biotinoyl-5′-AMP (bioAMP), which 
is stored in the active site of BirA*. bioAMP is then added to primary amine residues of a 
proximal protein. The BirA* tagging radius is thought to be about 100 angstroms (13). 
The result is a covalent attachment of biotin onto lysine and arginine residues of 
proteins proximal to BirA* at any time throughout the time course of an experiment. 
Additionally, the efficient conversion of biotin to bioAMP requires a higher-than 






















BirA* becomes useful as a biotin tagging mechanism when it is fused to a protein 
of interest (POI). In a living cell, it is assumed that a BirA*-POI construct will have the 
same function as the endogenous POI. Using cCE as the protein of interest, we created 
fusion constructs expressing BirA*-cCE. Proteins that associate with the expressed 
BirA*-cCE are considered interactors of cCE. By necessity, these interactors will be 
drawn close to BirA* during their association with the cCE. During this interaction time 
frame, BirA* can opportunistically label cCE-associating proteins, serving as a way to 
tag and later isolate associating proteins. Basal and off target biotin tagging events can 
Figure 3: Proximity-dependent biotinylation with BirA* fusion protein. 
A construct expressing the BirA* biotin ligase fused to a protein of 
interest is introduced into mammalian cells. While this protein is being 
expressed, biotin is supplemented into the media. The BirA* protein 
biotin tags proteins within a 100 Å radius in vivo. Tags proteins can be 
isolated from cell lysate by streptavidin affinity chromatography and 




be controlled for by expressing an empty BirA* construct and introducing the same level 
of biotin. 
 
Materials and Methods 
Plasmid constructs 
To generate pcDNA3.1-myc-BirA*-cCE, pcDNA3.1-myc-BirA* (Addgene plasmid #35700, 
Roux Lab) was first modified by Change-IT Site-Directed Mutagenesis using primers to 
change the NotI restriction site to a BsrGI restriction site, creating pcDNA3.1-myc-BirA*-
BsrGI. pcDNA3.1-myc-BirA*-cCE was generated by PCR-amplifying the cCE sequence 
from pcDNA3.1/TO-myc-cCE-bio [4] using PCR primers and inserting into XhoI-digested 
pcDNA3.1-myc-BirA*- BsrGI. To generate pcDNA3- FLAG-RNMT, human RNMT with an 
N-terminal FLAG tag and linker sequence was PCR-amplified and inserted into KpnI-
digested pcDNA3. To generate pcDNA3.1/TO-myc-BirA*-NES and pcDNA3.1/TO-myc-
BirA*-cCE, the Tet-operator sequence and NES sequence (to pcDNA3.1/TO-myc-BirA* 
only) were inserted using Change-IT Site-Directed Mutagenesis primers. All plasmid 
sequences were confirmed with Sanger sequencing. 
 
Cell Culture 
Human osteosarcoma (U2OS) cells obtained from ATCC (HTB-96) were cultured in 
McCoy's 5A medium (Thermo Fisher 116600–108) supplemented with fetal bovine 
serum (FBS) to 10% (v/v). Human embryonic kidney (HEK293) cells were cultured in 
Dulbecco's Modified Eagle Medium (Thermo Fisher 11995–073) supplemented with 
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FBS to 10% (v/v). Cells were maintained at 37°C under 5% CO2 and were discarded 
after 20 passages. 
 
Transfection and cytoplasmic fractionation 
Prior to transfection, cells were given fresh, pre-warmed medium. HEK293 or U2OS 
cells were 60–70% confluent at time of transfection. For the analysis of RNMT, HEK293 
cells were transfected with a 10-cm dish using jetPRIME transfection reagent (Polyplus 
114–15) according to manufacturer's protocol. For the analysis of Hsp90 and XPO2, 
U2OS cells were transfected with 6 μg plasmid DNA per 10-cm dish using FuGENE 6 
transfection reagent (Promega E2691) according to manufacturer's protocol. After 
centrifugation at 70 × g for 10 min at 4°C, pellets were resuspended in approximately 10 
volumes of ice-cold YO Lysis Buffer (10) (10 mM HEPES pH 7.3, 10 mM KCl, 10 mM 
MgCl2, 0.2% (v/v) IGEPAL CA-630, 2 mM dithiothreitol (DTT), 0.5 mM PMSF, 7.5 μl/ml 
protease inhibitor cocktail (Sigma P8340), 7.5 μl/ml phosphatase inhibitor cocktail 2 
(Sigma P5726), 7.5 μl/ml phosphatase inhibitor cocktail 3 (Sigma P0044)) by pipetting 
10 times. Resuspended cells were incubated on ice for 10 min, pipetted five times, and 
centrifuged at 16,100 × g for 10 min at 4°C. The supernatants (cytoplasmic extracts) 
were removed and kept on ice. Cytoplasmic protein concentration in each extract was 
determined by Bradford assay using Bio-Rad Protein Assay Dye Reagent (Bio-Rad 
5000006) normalized against a standard curve of BSA (Fisher Scientific BP1600–100). 





SDS-PAGE and western blotting 
Samples in Laemmli Sample Buffer were heated at 95 °C for 5 min and briefly 
centrifuged before loading Mini-PROTEAN TGX gels (Bio-Rad) and electrophoresing at 
150 V in Tris-glycine-SDS running buffer. Proteins were transferred to Immobilon-FL 
(EMD Millipore IPFL00010) PVDF membranes at 100 V for 60 min at 4 °C. Membranes 
were blocked in Blocking Buffer (TBS containing 3% (w/v) BSA) for at least 30 min at 
room temperature before incubating overnight at 4 °C in Blocking Buffer containing 
primary antibodies at the dilutions listed in the Antibodies section. Membranes were 
washed three times in TBS-T at room temperature, at least 10 min per wash. Secondary 
antibody incubations were performed for 30 min at room temperature in Blocking Buffer, 
with antibody dilutions listed in the Antibodies section. Membranes were washed again 
with TBST as before and then imaged with a Li-Cor Odyssey infrared scanner at 700 or 




Primary antibodies used in this study are as follows: mouse anti-myc (Santa Cruz 
sc-40; 1:1000 for WB, 1:1000 for IF), rabbit anti-XPO2/CSE1L (Proteintech; 1:1000), 
rabbit anti-HSP90α/β (Santa Cruz sc-4947; 1:2000), rabbit polyclonal anti-CE (Novus 
NBP1-49973; 1:2000), and mouse monoclonal anti-FLAG (Sigma F3165; 1:1000). Qdot 
800 streptavidin conjugate (Thermo Fisher Q10171MP; 1:10,000 for WB) was used to 





After 24 h induction with tetracycline-HCl, growth medium was completely 
removed from culture dishes. Cells were then washed with PBS and harvested by 
scraping into PBS. Samples prepared for mass spectrometry analysis that came from 
multiple dishes were pooled into a single centrifuge tube. Cytoplasmic extracts were 
prepared as previous described. To tubes containing 15 μL (stock slurry volume) of 
MyOne Streptavidin T1 Dynabeads (Thermo Fisher 65601), equal mass amounts of 
protein (amounts varied for WB experiments; 1.6 mg per sample used for mass 
spectrometry-analyzed samples) were added, brought to 500 µL with YO Lysis Buffer 
(Trotman et al., 2017), and brought to 150 mM upon addition of 15 μL of 5 M NaCl to 
constitute Pulldown Buffer containing recovered samples. For pulldowns done in 
Pulldown Buffer+SDS, 5 µL 10% (w/v) SDS was added to each 500 µL mixture to create 
a final concentration of 0.01% SDS per pulldown reaction. Tubes were incubated end-
over-end for 1 h at 4 °C to bind biotinylated proteins to the beads. The beads were 
washed 3 times with 500 μL of ice-cold YO Lysis Buffer containing 150 mM NaCl, 
incubating end-over-end at 4 °C for 10 min per wash. Mass spectrometry-analyzed 
samples were then washed 3 times with 500 μL of ice-cold 50 mM ammonium 
bicarbonate, incubating end-over-end at 4 °C for 10 min per wash. After removal of the 
final wash, beads were resuspended in either 20 µL 50 mM ammonium bicarbonate (for 
proteomics analysis) or 15-50 µL 2× Laemmli Sample Buffer (Bio-Rad 1610737) 
containing 5% (v/v) β-mercaptoethanol. Samples were stored at -20 °C or immediately 




RNMT analysis by transient transfection 
Triplicate cultures of HEK293 cells were transiently transfected with a 1:3 (w/w) ratio of 
pcDNA3-FLAG-RNMT and either pcDNA3.1-myc-BirA* or pcDNA3.1-myc-BirA*-cCE. 
The total amount of transfected DNA was 10 µg. After 6 h, a stock solution of 10 mM 
biotin (Sigma-Aldrich B4639–1G) in dimethylsulfoxide was prepared and added directly 
to medium to final concentrations of 5 and 25 μM biotin, or DMSO without biotin as a 
control. Additional DMSO was added where necessary to normalize the volume of mix 
added to each dish. Cells were incubated 14 h before harvesting and preparing 
cytoplasmic extracts as described above. Streptavidin pulldown was performed as 
described above, using 300 μg total cytoplasmic protein. Beads were resuspended in 
Laemmli Sample Buffer and analyzed by SDS-PAGE and western blot. Using the same 





Quantified cytoplasmic extracts (1000 µg each) were brought to 500 μl with Combo 
Buffer and pre-cleared with 15 μl slurry-equivalent of Dynabeads Protein G (Thermo 
Fisher 10003D) at 4°C for 45 min with end-over-end rotation. At the same time, 15 μl 
slurry-equivalent Dynabeads Protein G was incubated with 2 μg FLAG antibody in 500 
μl Combo Buffer (for each immunoprecipitation) at 25°C for 45 min. Pre-cleared extract 
samples were then incubated with bead-bound antibodies end-over-end at 4°C 
overnight. Beads were washed three times with 500 μl Combo Buffer, 10 min end-over-
15 
 
end at 4°C per wash. Beads were resuspended in to 2× Laemmli Sample Buffer for 
SDS-PAGE. 
 
Hsp90 and Exportin 2 analysis by transient transfection 
HEK293 cells were transiently transfected with either pcDNA3.1/TO-myc-BirA*-NES or 
pcDNA3.1/TO-myc-BirA*-cCE. The total amount of transfected DNA was 6 µg. After 6 h, 
1μM biotin was added directly to the medium. Cells were incubated 14 h before 
harvesting and preparing cytoplasmic extracts as described above. Streptavidin 
pulldown was performed as described above, using 1000 μg total cytoplasmic protein. 
Beads were resuspended in Laemmli Sample Buffer and analyzed by SDS-PAGE and 
western blot. An additional streptavidin pulldown was performed with 0.01% SDS as 
described above. 
   
Stable cell generation 
To generate stable U2OS-TR cell lines expressing BirA* and BirA*-cCE, U2OS-
TR cells were transfected with either pcDNA3.1/TO-myc-BirA*-NES or pcDNA3.1/TO-
myc-BirA*-cCE using FuGene 6 (Promega E2691) according to manufacturer’s 
instructions. Cells were passaged two days following transfection and then maintained 
for two weeks in medium containing 600 μg/mL Geneticin (Thermo Fisher 10131035). 
Maintaining selective pressure with 600 μg/mL Geneticin, BirA* cells were passaged to 
low densities to allow formation of individual colonies that were isolated using cloning 
cylinders. Cell lines were expanded over several weeks in medium containing 600 
μg/mL Geneticin before confirming inducible expression of myc-BirA*. Myc-BirA*-cCE 
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were maintained in antibiotic as described above but were not isolated as single 
colonies. Inducible expression of each cell line was confirmed by western blotting and 
immunofluorescence as described below. 
 
Immunofluorescence 
Glass coverslips in the wells of a 24-well plate were each seeded with 50,000 
stable cells 17 h prior to induction. Expression of BirA* was induced by addition of 0.02 
µg/mL tetracycline-HCl BirA*-cCE was induced by addition of 0.2 µg/mL tetracycline-
HCl. After 24 h, medium was removed from the coverslips, and the cells were fixed for 
20 min at room temperature in PBS containing 4% formaldehyde and 0.2% (v/v) Triton 
X-100. Coverslips were briefly washed three times with PBS before incubating in IF 
Block Solution (PBS containing 1% (w/v) BSA and 0.05% (v/v) Triton X-100) for 90 min 
at room temperature, followed by overnight incubation at 4 °C in IF Blocking Solution 
containing a 1:1000 dilution of mouse anti-myc antibody (Santa Cruz sc-40). Coverslips 
were washed three times with IF Wash Solution (PBS containing 0.5 mM MgCl2 and 
0.05% (v/v) Triton X-100) at room temp, 5 min per wash, and then incubated for 60 min 
in the dark at room temp in IF Block Solution containing 0.75 μg/mL DAPI and a 1:1000 
dilution of anti-mouse Alexa Fluor 594 (Thermo Fisher A11005). After washing with IF 
Wash Solution as before, coverslips were mounted on glass microscope slides with 
ProLong Gold Antifade Mountant (Thermo Fisher P36930), and incubated overnight in 
the dark at room temp to allow the mountant to cure. Images were acquired at room 
temp with a Nikon Eclipse Ti-U inverted microscope fitted with a CFI Plan Apo VC 60X 
oil immersion objective and a Nikon DS-Qi1 monochrome digital camera. Images were 
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analyzed using Nikon NIS-Elements AR 3.10 software. Specificity of the secondary 
antibody for the primary antibodies was confirmed by parallel preparation of control 
coverslips not treated with primary antibody. 
 
Proteomics analysis 
Beads from streptavidin pulldowns were reconstituted in 80 μL of 50 mM 
ammonium bicarbonate containing 0.02% ProteaseMAX surfactant (Promega V2071) 
and incubated at 95 °C for 5 min. After adding 13 μL of 50 mM ammonium bicarbonate, 
1 μL of 0.5 M DTT was added, and samples were incubated at 56 °C for 20 min for the 
reduction of disulfides. Cysteine alkylation of was then performed by adding 3 μL of 0.55 
M iodoacetamide and incubating at room temp in the dark for 15 min. Tryptic digests 
were performed by adding 1 μL of 1% ProteaseMAX surfactant and 2 μL of 1 μg/μL 
trypsin and incubating at 37 °C for 3 h. Trypsin was inactivated upon addition of 
trifluoroacetic acid (TFA) to a final concentration of 0.5%. The digestion products were 
centrifuged 16,000 × g for 10 min, and the supernatants were cleaned up with C18 
cartridge columns. Approximately 0.5 μg of peptides per sample were separated by 
reversed-phase ultra-performance liquid chromatography (RP-UPLC) on a Waters 
nanoACQUITY UPLC system and mass analyzed by a ThermoFisher Orbitrap Elite 
using top 15 data dependent acquisition in positive ion mode. 
 
Results 
BioID confirms known cytoplasmic capping complex members. 
18 
 
BirA* and Myc tags were added to the N-terminus of a form of CE that is restricted to 
the cytoplasm due to loss of the NLS (nuclear localization sequence) and addition of the 
HIV Rev NES nuclear export sequence) to create myc-BirA*-cCE. These modifications 
to CE were originally shown to be sufficient to restrict CE almost completely to the 
cytoplasm (6). A parallel construct expressing myc-BirA* without CE was used as a 
control for non-specific biotinylation.  
These constructs were first used to determine if there was a proximal relationship 
between cCE and RNMT (cap-methyltransferase). RNMT protein was previously shown 
to be expressed in the cytoplasm of U2OS cells (11). Initially, an approach was taken to 
preferentially recover endogenous RNMT from cytoplasmic extracts in the presence of 
BirA*-cCE. But, endogenous RNMT was not detected by western blot. This may have 
been due to the low level of cytoplasmic RNMT compared to other members of the 
cytoplasmic capping complex. We then moved to a co-transfection approach in which 
we overexpressed a tagged form of RNMT together with a BirA* construct. Plasmids 
expressing either myc-BirA* or myc-BirA*-cCE were transfected into HEK293 cells 
together with a second plasmid expressing FLAG-RNMT and incubated for 6 h. Cells 
were then cultured for 14 h in the same medium supplemented 0, 5 or 25 μM biotin. 
Cytoplasmic extracts recovered on streptavidin beads were then analyzed by western 
blotting using antibodies against the FLAG tag, Nck1, and RAM. 
Cytoplasmic BirA* and BirA*-cCE were expressed regardless of biotin 
supplementation (Figure 4A, left panel), and their recovery on streptavidin beads shows 
that biotinylation events are dependent on biotin supplementation (Figure 4A, right 
panel). The recovery of Nck1 from only from cells expressing BirA*-cCE confirmed the 
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utility of BioID for identifying known cytoplasmic capping complex components. 
Selective recovery of RNMT confirmed its identification as a component of the 
cytoplasmic capping complex. In addition, the absence of GAPDH, a highly expressed 
and assumed unrelated cytoplasmic enzyme, confirmed the specific biotin labeling of 
proteins in the cytoplasmic capping complex. RNMT functions as a heterodimer with a 
118-amino acid protein termed RNMT-activating miniprotein (RAM) (12) RAM is 
necessary for stabilization of RNMT in the cytoplasm but is not though to have catalytic 
activity related to cytoplasmic 5’ capping. RAM was present in the input cytoplasmic 






































These results do not indicate if RNMT and RAM themselves were biotinylated by 
BirA*-cCE or if their recovery was caused by an association to some other biotinylated 
protein. To address this, FLAG-RNMT was recovered from the same extracts by 
Figure 4: BioID identifies Nck1, RNMT, and RAM as members of the cytoplasmic 
capping complex. A: HEK293 cells were cotransfected with plasmids expressing 
either Myc-BirA* or Myc-BirA*-cCE together with FLAG-RNMT.  After transfection, 
cells were supplemented with either 5 or 25 µM biotin in DMSO, or with only 
DMSO vehicle as a control. Cytoplasmic extracts were isolated and biotinylated 
proteins were recovered on streptavidin beads. Recovered samples were analyzed 
by western blotting with antibodies against Myc (to visualize BirA* and BirA*-
cCE), Nck1, FLAG (to visualize FLAG-RNMT), RAM, and GAPDH. B: The same 
cytoplasmic extracts were immunoprecipitated using the antibody against the 
FLAG tag used in (A). IP samples were analyzed by western blot with antibodies 
against RNMT and RAM to confirm their recovery. The open circle in the RNMT 
panel represents the heavy chain of the FLAG antibody. The same IP samples 
were then probed with streptavidin to visualize biotin tagging of proteins. The 
sizes of RNMT, RAM, and an unknown protein denoted by a black dot are 




immunoprecipitation, and biotinylated proteins were visualized by streptavidin western 
blot (Figure 4B). The recovery of RAM with RNMT confirmed that these proteins interact 
with each other in the cytoplasm. Streptavidin western blotting showed RNMT was 
biotinylated by BirA*-cCE. RAM was not detected with streptavidin. This could be either 
to RAM being too far away from BirA* in complex to be biotinylated or because of a 
shielding by effect by RNMT. Regardless of the biotinylation state of recovered proteins, 
the propensity for RNMT and RAM to be preferentially recovered in BirA*-cCE samples 
suggests that they are members of a cytoplasmic capping complex. FLAG-RNMT also 
recovered a 30 kDa protein (solid dot) whose biotinylation by BirA*-cCE identified it as 
an unknown constituent of the cytoplasmic capping complex that may contribute to cap 
methylation. This protein has yet to be identified. 
Experiments in (10) performed by Jackson Trotman using recombinant forms of 
tagged RNMT and tagged CE suggested that RNMT and CE can bind directly to each 
other in vitro. Jackson expanded these results using a bio-cCE construct transfected 
into HEK293 cells along with along with one of three forms of RNMT (either full length, 
N-terminal deletion, or catalytic C-terminal deletion). Streptavidin recovery of bio-cCE as 
a bait protein brought along both full-length RNMT and the N-terminal deletion 
construct. Thus, residues within the C-terminal methyltransferase domain seem to be 
responsible for recruitment of RNMT into the cytoplasmic capping complex. These data, 
along with proximity dependent biotinylation of FLAG-RNMT using BirA*-cCE indicates 
that RNMT is recruited as a member of the cytoplasmic capping complex via a direct 





BioID confirms association of ∆N-RNMT to the cytoplasmic capping complex  
As part of work to determine whether RNMT was responsible for the catalysis of 
the N7 methylation of the cytoplasmic cap, a catalytically inactive form of RNMT was 
constructed by Jackson Trotman, termed ∆N-RNMT. The D203A mutation in the 
otherwise intact C-terminal domain disrupts S-Adenosyl methionine (SAM), the methyl 
group donor needed or RNMT catalysis, from binding to its binding pocket on RNMT 
(Figure 6A). Notably, ∆N-RNMT retains the ability to bind RAM. In order for ∆N-RNMT 
to be considered a dominant-negative inhibitor of cytoplasmic capping, it was necessary 
to establish that expressed ∆N-RNMT is capable of associating with the cytoplasmic 
capping complex in a manner indistinguishable to that of wild-type RNMT. This question 
was examined in an experiment parallel to that shown in Figure 4A, in which a co-




transfection of BirA*-cCE or BirA* and FLAG-∆N-RNMT was supplemented with biotin 
before performing a streptavidin pulldown and western blot analysis.  Selective recovery 
of ∆N-RNMT with BirA*-cCE only in during biotin supplementation (Figure 6B, right 
panel) mirrored the result shown with wild-type RNMT (Figure 4B, right panel) indicating 
that the catalytically inactive ∆N-RNMT mutant interacts with the cytoplasmic capping 
















Transfection of a plasmid expressing ∆N-RNMT results in a highly expressed, 
catalytically inactive form of RNMT that is still able to associate with members of the 
Figure 6: ∆N RNMT interacts with cCE in a manner indistinguishable to wild-
type RNMT. A: A schematic of the FLAG-∆N-RNMT construct and how it differs 
from the FLAG-RNMT construct used in Figure 4. B: Cells were transfected and 
prepared as in Figure 4A, except that FLAG-RNMT was replaced with FLAG-
∆N-RNMT. Recovered samples were analyzed with antibodies against Myc (to 
visualize Myc-BirA* and Myc-BirA*-cCE) and FLAG (to visualize FLAG-∆N-




cytoplasmic capping complex (Figure 6). This situation presumably results in majority of 
cytoplasmic capping machinery associating in complexes that include ∆N-RNMT 
instead of wild-RNMT. Such complexes are predicted to be catalytically incomplete, 
because ∆N-RNMT is unable to complete cap methylation. This is likely to result in a 
reduced ability to create mature caps in the cytoplasm. This hypothesis was confirmed 
by Jackson Trotman by using expression of ∆N-RNMT to destabilize known mRNA 
targets of cytoplasmic recapping and confirm that catalytically active RNMT is essential 







BioID validates novel protein interactors of cCE by western blot 
A recent search for novel interactors (Jackson Trotman) of cCE using mass 
spectrometry (Bernice Agana) has elucidated several possible proteins that associate 
Figure 7: Schematic showing the interaction ∆N RNMT with the cytoplasmic 
capping complex. ∆N-RNMT sequesters away cytoplasmic capping complex 
machinery from wild-type RNMT. Cytoplasmic capping complexes that do 
not contain wild-type RNMT are incapable of methylating the re-constituted 
cap. An unmethylated cap is recognized by exonucleases in the cytoplasm, 




with cCE and/or the cytoplasmic capping complex. This approach involved using a 
tagged form of cCE as a bait protein. After a 24 h expression of this bio-cCE plasmid, 
U2OS cells were gently crosslinked with formaldehyde to preserve protein-protein 
interactions and any RNA-protein interactions. Both the α and β isoforms of HSP90 
were identified by this proteomics analysis as cCE-interacting proteins. HSP90 is a well-
characterized, ATP-dependent protein chaperone that helps fold and stabilize a select 
but diverse group of client proteins. HSP90 functions as a chaperone constitutively, but 
its expression increases in response to protein-denaturing stressors to help stabilize 
client proteins (14). 
I confirmed the in vivo interaction between cCE and Hsp90 using proximity-
dependent biotinylation. HEK293 cells were transfected with either BirA*-cCE or BirA*-
NES (figure 8A), and incubated in the presence of 1 µM biotin for 14 h. 24 h after 
transfection, cytoplasmic extracts were prepared and biotinylated were recovered on 
streptavidin beads. The preferential recovery of HSP90 from cells expressing BirA*-


















The same method was used to validate the recovery of Exportin-2 (XPO2) (Figure 8B), 
a nuclear export receptor. Due to high background signal in pulldown samples from the 
negative control (BirA*-NES alone) seen for both HSP90 and XPO2, the pulldown using 
the same cytoplasmic extracts was repeated with 0.01% SDS to disrupt weaker, non-
covalent protein-protein interactions. Proteins that were residually bound to streptavidin 
beads can then be more easily removed in subsequent washing steps. This lowers the 
level of off-target pulldown events but largely leaves the extremely tight association 
































Figure 8: Validation of Hsp90 and Exportin 2 as protein interactors of cCE. 
A: Myc-BirA* and Myc-BirA*-cCE were transiently transfected into 
HEK293 cells. Cytoplasmic extracts were prepared to measure the 
expression of each construct by western blot with an anti-Myc antibody. 
B: Proteins from the same extracts were recovered on streptavidin beads 
and analyzed by western blot with antibodies against Hsp90 and 
exportin-2. C: The experiment in (B) was repeated, except that 0.1% SDS 
was added to the Pulldown Buffer at the beginning of the streptavidin 




previous BioID studies (8). Introduction of SDS during streptavidin recovery significantly 
reduced the levels of Hsp90 recovered in the control samples while preserving the 
association between biotinylated Hsp90 and streptavidin in the BirA*-cCE sample 
(Figure 8C). Based on this result, SDS addition during streptavidin recovery was used 
during subsequent proteomic experiments to reduce the levels of recovered proteins in 
the control samples. 
 
Mass spectrometry analysis of the cCE interactome using BioID 
 The main utility of BioID lies in the ability to identify novel interactors of a protein 
of interest using a mass spectrometry approach. To this end, U2OS cells were 
transfected with either pcDNA3.1/TO-myc-BirA*-NES or pcDNA3.1/TO-myc-BirA*-cCE. 
The backbone plasmid, pcDNA3.1, includes a neoR gene that confers resistance to the 
antibiotic Geneticin (G418). Cells with integrated plasmid DNA were selected for using 
600 µg/mL G418. After about 2 weeks, individual colonies were isolated using cloning 
cylinders and grown to confluency as a clonal line. These cells were tested for their 
expression level of BirA* or BirA*-cCE using 1 µg/mL Doxycycline (data not shown). The 
BirA* control showed robust overexpression as expected, but the BirA*-cCE clones 
showed no detectable expression by western blot. To navigate this issue, a second 
G418 screen was conducted, and G418-resistant cells were pooled (individual clones 
were not isolated). This approach yielded a polyclonal mixture of BirA*-cCE expressing 
cells.  
 To recapitulate the most physiological cell conditions during proximity-dependent 
biotinylation, I decided to manipulate the expression level in stable cell lines by testing 
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various amounts of tetracycline-HCl, a doxycycline analog (figure 9). This approach 
allowed the expression of BirA*-cCE to mimic the physiological expression endogenous 
cCE. I first used an antibody against CE to directly compare BirA*-cCE to endogenous 
cCE expression from the same cytoplasmic extracts (Figure 9A). I decided that 0.2 
µg/mL Tet-HCl best matched induced expression to endogenous expression. I then 
conducted a similar titration for the control line, BirA*. In order to directly compare BirA* 
to BirA*-cCE expression, I utilized a Myc tag present on the N-terminus of the BirA* 
protein in both the BirA* control and BirA*-cCE. I used an anti-myc antibody to visualize 
the expression of myc-BirA* and myc-BirA*-cCE on the same western blot. BirA* 
induction using 0.02 µg/mL Tet-HCl most closely matched the expression level of BirA*-
cCE (Figure 9B). Using these levels of induction, immunofluorescence microscopy was 
used to characterize the subcellular localization of the tagged protein in each cell line. 
Both proteins seem to be nearly completely cytoplasmically localized (Figure 9C). About 
90% of cells from the clonal BirA* line have a similar low level of expression (using anti-
Myc primary antibody, stained red). The polyclonal BirA*-cCE line shows about 50% of 
cells expressing at a higher level, while other cells are unresponsive to induction, 
consistent with the observation that three isolated clonal cell lines did not express BirA*-
cCE. These results are consistent with the western blot data in Figure 9B, in which the 
average expression of any given cell in the population is similar between the control and 
experimental lines. These two cell lines improve the scope of the BioID experiment by 
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Figure 9: Characterization of stable UTOSTR cells used for proteomics. A: Cells 
transfected with BirA*-cCE were selected for using G418. These cells were 
exposed to various amounts of Tet-HCl to determine their responsiveness to 
induction. The expression level of BirA*-cCE (induced) was compared to 
endogenous cCE expression using an antibody against CE. 0.2 µg/mL was chosen 
as it produced an expression level of BirA*-cCE most similar to that of 
endogenous cCE. B: Tetracycline induction (at various concentrations) 
comparing BirA* expression to 0.2 µg/mL Tet-HCl-induced BirA*-cCE expression.  
C: Expression pattern of BirA* and BirA*-cCE while induced with established 
concentrations of Tet-HCl. 
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To prepare samples for mass spectrometry analysis, concentrations of Tet-HCl 
were used to induce expression of BirA* or BirA*-cCE at near-physiological level, as 
discussed above. Samples were prepared in triplicate. Six hours after induction, 10 µM 
biotin was directly added to the culture media. Twenty-four hours after induction, cells 
were harvested and streptavidin pulldowns were conducted using SDS-supplemented 
Pulldown Buffer as discussed above. Each pulldown reaction used 1.6 mg cytoplasmic 
protein quantified by Bradford assay. After washes, on-bead trypsin digestion was 
performed in preparation for liquid chromatography coupled to tandem mass-
spectrometry (LC-MS/MS). MS/MS spectra were searched against a database 
containing tryptic peptide sequences of the human proteome, and the number of 
peptide spectral matches (PSMs) were tallied for each protein identified. Results from 
three independent experiments are presented in Table 1, with proteins sorted by 
enrichment in the BirA*-cCE samples over the BirA* samples. The analysis was filtered 
to exclude obvious peptide contaminants as well as BirA* and BirA*-cCE proteins 
themselves to allow for analysis of proteins with less sample representation. 
Surprisingly, no peptides identified for the known cCE-interacting proteins Nck1 or 
RNMT. The reason for this is unknown but could be caused by less-abundant peptide 
signals being overwhelmed by those from more abundant proteins during MS/MS 
analysis.  
Because of the numerous peptide identifications enriched in the BirA*-cCE 
samples, it appears that cCE forms protein complexes beyond the previously described 
cytoplasmic capping complex. Many of these proteins are exclusively cytoplasmic, 
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suggesting that the cytoplasmic pool of CE has distinct function not present in the larger 













 The mass spectrometry results garnered by BioID were then compared to the 
results from the pulldown of cCE following formaldehyde crosslinking (performed by 
Jackson Trotman) that was described above. Several of the BirA*-cCE highly-enriched 
PSMs identified by BioID were also identified as high-confidence PSMs by the 
crosslinking approach. These proteins are summarized in Table 2. Because many 
peptides were identified by both approaches, each method serves as a means of 
external validation for the other. This overlap suggests that enriched proteins are indeed 
real cCE interactors as opposed to an anomaly due to an uncontrolled aspect of the 
BioID experimental design. 
Accession Gene Symbol Gene Name cCE 1 PSMs cCE 2 PSMs cCE 3 PSMs BirA 1 PSMs BirA 2 PSMs BirA 3 PSMs Sum cCE Sum BirA Avg. cCE Avg. BirA cCE Enrichment Index
P35579 MYH9 Myosin-9 1 4 20 2 25 2 8.3 0.7 5.00
P49327 FASN Fatty acid synthase 8 8 25 5 1 2 41 8 13.7 2.7 3.73
P50990 CCT8 T-complex protein 1 subunit theta 2 2 7 1 11 1 3.7 0.3 2.75
P13639 EEF2 Elongation factor 2 7 7 0 2.3 0.0 2.33
P26038 MSN Moesin 8 2 11 4 2 1 21 7 7.0 2.3 2.10
P07437 TUBB Tubulin beta chain 27 19 55 19 15 18 101 52 33.7 17.3 1.84
P30101 PDIA3 Protein disulfide-isomerase A3 5 9 8 8 1 22 9 7.3 3.0 1.83
Q9NRR2 TPSG1 Tryptase gamma 7 1 7 1 2.3 0.3 1.75
P49321 NASP Nuclear autoantigenic sperm protein 2 8 4 3 2 14 5 4.7 1.7 1.75
P68371 TUBB4B Tubulin beta-4B chain 22 17 49 18 13 17 88 48 29.3 16.0 1.73
P07355 ANXA2 Annexin A2 9 6 12 8 2 3 27 13 9.0 4.3 1.69
P29692 EEF1D Elongation factor 1-delta 5 6 5 5 2 16 7 5.3 2.3 1.60
Q13085 ACACA Acetyl-CoA carboxylase 1 49 48 66 44 15 41 163 100 54.3 33.3 1.58
P68363 TUBA1B Tubulin alpha-1B chain 24 10 41 17 12 16 75 45 25.0 15.0 1.56
P11021 HSPA5 78 kDa glucose-regulated protein 10 24 11 21 5 45 26 15.0 8.7 1.55
P04792 HSPB1 Heat shock protein beta-1 6 8 7 7 3 1 21 11 7.0 3.7 1.50
P15311 EZR Ezrin 9 2 14 9 3 2 25 14 8.3 4.7 1.47
P16949 STMN1 Stathmin 7 8 4 5 5 19 10 6.3 3.3 1.46
P06733 ENO1 Alpha-enolase 27 29 33 39 15 4 89 58 29.7 19.3 1.46
P06753 TPM3 Tropomyosin alpha-3 chain 2 7 1 3 1 10 4 3.3 1.3 1.43
P08238 HSP90AB1 Heat shock protein HSP 90-beta 18 5 22 8 8 13 45 29 15.0 9.7 1.41
P07195 LDHB L-lactate dehydrogenase B chain 8 2 11 5 4 3 21 12 7.0 4.0 1.40
P07900 HSP90AA1 Heat shock protein HSP 90-alpha 12 3 18 7 5 9 33 21 11.0 7.0 1.38
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 9 7 7 9 5 23 14 7.7 4.7 1.35
P43358 MAGEA4 Melanoma-associated antigen 4 1 3 4 0 1.3 0.0 1.33
P63313 TMSB10 Thymosin beta-10 4 4 0 1.3 0.0 1.33
Q09666 AHNAK Neuroblast differentiation-associated protein AHNAK 98 194 124 156 70 84 416 310 138.7 103.3 1.33
P07237 P4HB Protein disulfide-isomerase 13 18 10 20 5 3 41 28 13.7 9.3 1.32
P37802 TAGLN2 Transgelin-2 5 14 6 12 3 1 25 16 8.3 5.3 1.32
P14618 PKM Pyruvate kinase PKM 14 5 20 12 10 5 39 27 13.0 9.0 1.30
P07737 PFN1 Profilin-1 4 1 5 4 1 10 5 3.3 1.7 1.25
P60174 TPI1 Triosephosphate isomerase 15 15 15 23 10 45 33 15.0 11.0 1.25
Accession Gene Symbol Gene Name cCE 1 PS s cCE 2 PS s cCE 3 PS s BirA 1 PSMs BirA 2 PSMs BirA 3 PSMs Sum cCE Sum BirA Avg. cCE Avg. BirA cCE Enrichment Index
P35579 MYH9 Myosin-9 1 4 20 2 25 2 8.3 0.7 5.00
P49327 FASN Fatty acid synthase 8 8 25 5 1 2 41 8 13.7 2.7 3.73
P50990 CCT8 T-complex protein 1 subunit theta 2 2 7 1 11 1 3.7 0.3 2.75
P13639 EEF2 Elongation factor 2 7 7 0 2.3 0.0 2.33
P26038 MSN Moesin 8 2 11 4 2 1 21 7 7.0 2.3 2.10
P07437 TUBB Tubulin beta chain 27 19 55 19 15 18 101 52 33.7 17.3 1.84
P30101 PDIA3 Protein disulfide-isomerase A3 5 9 8 8 1 22 9 7.3 3.0 1.83
Q9NRR2 TPSG1 Tryptase gamma 7 1 7 1 2.3 0.3 1.75
P49321 NASP Nuclear autoantigenic sperm protein 2 8 4 3 2 14 5 4.7 1.7 1.75
P68371 TUBB4B Tubulin beta-4B chain 22 17 49 18 13 17 88 48 29.3 16.0 1.73
P07355 ANXA2 Annexin A2 9 6 12 8 2 27 13 9.0 4.3 1.69
P29692 EEF1D Elongation factor 1-delta 5 6 5 5 2 16 7 5.3 2.3 1.60
Q13085 ACACA Acetyl-CoA carboxylase 1 49 48 66 44 15 41 163 100 54.3 33.3 1.58
P68363 TUBA1B Tubulin alpha-1B chain 24 10 41 17 12 16 75 45 25.0 15.0 1.56
P11021 HSPA5 78 kDa glucose-regulated protein 10 24 11 21 5 45 26 15.0 8.7 1.55
P04792 HSPB1 Heat shock protein beta-1 6 8 7 7 3 1 21 11 7.0 3.7 1.50
P15311 EZR Ezrin 9 2 14 9 3 2 25 14 8.3 4.7 1.47
P16949 STMN1 Stathmin 7 8 4 5 5 19 10 6.3 3.3 1.46
P06733 ENO1 Alpha-enolase 27 29 33 39 15 4 89 58 29.7 19.3 1.46
P06753 TPM3 Tropomyosin alpha-3 chain 2 7 1 3 1 10 4 3.3 1.3 1.43
P08238 HSP90AB1 Heat shock protein HSP 90-beta 18 5 22 8 8 13 45 29 15.0 9.7 1.41
P07195 LDHB L-lactate dehydrogenase B chain 8 2 11 5 4 3 21 12 7.0 4.0 1.40
P07900 HSP90AA1 Heat shock protein HSP 90-alpha 12 3 18 7 5 9 33 21 11.0 7.0 1.38
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 9 7 7 9 5 23 14 7.7 4.7 1.35
P43358 MAGEA4 Melanoma-associated antigen 4 1 3 4 0 1.3 0.0 1.33
P63313 TMSB10 Thymosin beta-10 4 4 0 1.3 0.0 1.33
Q09666 AHNAK Neuroblast differentiation-associated protein AHNAK 98 194 124 156 70 84 416 310 138.7 103.3 1.33
P07237 P4HB Protein disulfide-isomerase 13 18 10 20 5 41 28 13.7 9.3 1.32
P37802 TAGLN2 Transgelin-2 5 14 6 12 3 1 25 16 8.3 5.3 1.32
14618 PKM Pyruvate kinase PKM 14 5 20 12 10 5 39 27 13.0 9.0 1.30
P07737 PFN1 Profilin-1 4 1 5 4 1 10 5 3.3 1.7 1.25
P60174 TPI1 Triosephosphate isomerase 15 15 15 23 10 45 33 15.0 11.0 1.25
Table 1: Identification of human peptides interacting with cCE using mass spectrometry. 







 The main aims of this project have been successfully explored. The BioID 
technology originally established in a perinuclear protein complex has been successfully 
altered to study cCE and its interactors. BirA*-cCE can be transiently transfected in 
HEK293 cells to overexpress the protein. Or, BirA*-cCE can be inducibly expressed at a 
moderate level in U2OS-TR cells to mimic the expression profile of endogenous cCE. 
The ability for the BioID technology to biotin-tag proteins in vivo provides a history of 
protein interactions over the course of an experimental time course. This novel 
approach provides a means of independent validation of other methods to study protein-
proteins interactions and can dramatically strengthen the argument that two proteins 
associate in vivo. It can also expand the list of interacting factors compared to those 
identified by traditional pulldown experiments, because even transiently-interacting 
proteins have the potential to be biotin-tagged.  
The utility of BioID to not only validate members of the core cytoplasmic capping 
complex but also to expand the cCE interactome has proven to a be a valuable tool to 
Table 2: A summary of peptides that were identified by both the crosslinking-pulldown 




explore the other potential functions of cCE. Based on the identification of proteins 
previously unknown to interact with capping enzyme, it is likely that the impact of cCE 
extends beyond a simple guanylyltransferase for a subset of cytoplasmic mRNAs. The 
exploration of a functional relationship of many proteins identified in Table 1 to cCE is a 
direction for future research. Many of the potential interactors have been shown to have 
RNA binding capability, but their impact on mRNA recapping specifically is not known. It 
is possible to some of these proteins are previously unknown factors that assemble with 
the core cytoplasmic capping complex on Nck1 and are necessary for formation of a 
stable cytoplasmic capping complex. Alternatively, these proteins may populate new 
protein complexes altogether, and cCE may be a common factor to multiple different 
cytoplasmic protein complexes. 
Of the proteins identified, only Hsp90 has been explored in detail. Compounds 
that inhibit the chaperone function of Hsp90 can reduce the levels of both cytoplasmic 
and nuclear CE, suggesting that Hsp90 functions to stabilize cCE and reduce its 
turnover (11). Presumably, inhibition of Hsp90 also affects the recapped transcriptome, 
although this has yet to be established. As with Hsp90, many other proteins identified by 
both proteomic methods deserve further exploration to understand their functional 
relationship to cCE. One protein of immediate interest is fatty-acid synthase (FASN), 
because of its strong enrichment in both proteomics methods. FASN is a known RNA 
binding protein, and preliminary data suggests that functional Hsp90 is required to 
mediate the interaction between cCE and FASN. It is possible that the cCE-FASN 
interaction is necessary for effective cCE enzymatic activity. Alternatively, cCE may be 
contributing to efficient fatty-acid synthesis. Although the functional role of this 
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interaction is not yet characterized, it is becoming increasingly clear that cCE is 
contributing to cell processes other than its known role in cytoplasmic recapping. 
There are also several proteins that are either themselves components of the 
cytoskeleton (multiple tubulins, myosin-9, stathmin) or involved in the attachment of the 
cytoskeleton to the plasma membrane (moesin, ezrin, annexin A2). cCE’s potential role 
within the cytoskeleton is also unknown. One possibility is that cCE is mediating 
cytoskeletal changes that occur near the plasma membrane. Or, these cytoskeletal 
components could be recruit intact cytoplasmic recapping complexes to the cell 
periphery as a mechanism to regulate the cap status of transcripts on a local level. This 
recruitment would seemingly affect only a fraction of the total cCE pool, since cCE has 
been shown to be distributed throughout the entire cytoplasm including at the plasma 
membrane in several cell types (Schoenberg Lab, unpublished). 
The current list of cCE interacting proteins is likely incomplete. There are several 
previously characterized cCE interactors that do not appear on my list, including Nck1 
and RNMT. In addition to these known interactors, other potential complex members, 
like a 5’ kinase and 2’O methyltransferase also do not appear. There are multiple 
explanations for these observations. The first is that these proteins are not sufficiently 
biotin-tagged under the specific experimental conditions used in mass spectrometry 
experiment. Because the molar concentration of proteins can vary over several orders 
of magnitude, it is likely that some interactors are incompatible for biotin-tagging due to 
low protein levels. In addition to these biological explanations, other issues likely arise 
during proteomic analysis. The ability for different peptides to be detected by the mass 
analyzer will vary and affect the success of identification of a mass to charge ratio. And, 
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at any given time, only the 15-most abundant peptides will be analyzed; it is possible 
that proteins that are bead-recovered at a low level will fall under the threshold of 
detection. It may be possible to intentionally exclude very abundant interactors during 
future mass spectrometry analyses, which would potentially allow for the detection of 
proteins recovered at a lower level. All of these issues are potential sources of error, but 
nonetheless, the current list of identified proteins provides several interesting routes for 
future research.  
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